US · AVDL
Avadel Pharmaceuticals plc
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Dublin 2
- Website
- avadel.com
Price · as of 2024-12-31
—
Market cap 1.83B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $80.74 | — |
| Intrinsic Value(DCF) | $48.66 | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $6.17 | $104.91 | $0.83 | $0.00 | $1.23 |
| 2011 | $6.93 | $22.78 | $0.47 | $0.00 | $1.26 |
| 2012 | $4.04 | $24.32 | $0.48 | $0.00 | $1.42 |
| 2013 | $10.10 | $42.74 | $0.00 | $0.00 | $8.89 |
| 2014 | $17.26 | $32.62 | $0.00 | $0.00 | $57.63 |
| 2015 | $9.44 | $439.37 | $352.05 | $6.23 | $1,035.92 |
| 2016 | $10.26 | $44.36 | $207.12 | $0.00 | $4.50 |
| 2017 | $7.29 | $51.51 | $438.33 | $9.94 | $37.36 |
| 2018 | $1.99 | $248.47 | $0.00 | $0.00 | $77.42 |
| 2019 | $9.88 | $36.63 | $0.00 | $0.00 | $28.98 |
| 2020 | $9.77 | $35.38 | $2.07 | $3.41 | $0.00 |
| 2021 | $7.22 | $48.13 | |||
| 2022 | $8.70 | ||||
| 2023 | $16.35 | $0.00 | $0.00 | ||
| 2024 | $7.91 | $80.74 | $8.14 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Avadel Pharmaceuticals plc's (AVDL) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $80.74
- Current price
- —
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$48.66
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| AVDL | Avadel Pharmaceuticals pl… | $18.96 | 1.83B | +326% | +157% | — | — | -15.41 | 10.19 | 4.45 | -19.13 | — | 13.20 | 90.97% | -25.07% | -28.87% | -60.44% | -426.40% | -29.69% | 0.02 | -3.91 | 2.75 | 2.21 | 1.40 | -7450.00% | 50479.00% | -6350.00% | -6.23% | -0.96 | -474.12% | 0.00% | 0.00% | 7.16% | -16.05 | -14.51 | 4.02 | -0.97 |
| ALVO | Alvotech | $4.88 | 1.52B | +1,171% | -9% | — | — | -12.88 | -7.24 | 6.10 | -127.84 | — | -6.72 | 62.16% | 14.22% | -47.35% | 34.47% | 16.24% | -21.36% | -2.88 | 0.44 | 2.35 | 1.57 | -35.28 | -6420.00% | 43556.00% | -1807.00% | -9.84% | -1.22 | -68.51% | 0.00% | 0.00% | 0.00% | 59.25 | -14.04 | 8.43 | -0.85 |
| ANIP | ANI Pharmaceuticals, Inc. | $92.62 | 2.01B | +4% | +2,338% | -54% | +111% | 19.26 | 2.79 | 1.71 | 7.47 | — | -1176.59 | 0.00% | 12.58% | 8.87% | 16.16% | 12.26% | 5.75% | 0.60 | 5.54 | 2.71 | 2.04 | 0.19 | -41923.00% | 4378.00% | 29356.00% | 12.28% | 0.67 | 25.00% | 0.08% | 1.50% | 30.03% | 13.93 | 8.36 | 1.75 | 2.25 |
| BGM | BGM Group Ltd. | $9.89 | 1.98B | +329% | -45% | -50% | -28% | -40.44 | 1.44 | 2.44 | 49.11 | — | 1.61 | 16.39% | -2.25% | -5.75% | -3.55% | -1.76% | -2.91% | 0.00 | -0.88 | 3.39 | 2.73 | -11.16 | -8148.00% | -4599.00% | -43.00% | -5.52% | 0.06 | -14.87% | 0.00% | 0.00% | 4.76% | -76.65 | -12.76 | 1.72 | 5.16 |
| EVO | Evotec SE | $3.35 | 1.19B | +735% | -43% | — | — | -5.60 | 1.15 | 1.38 | -14.20 | -3.91 | 1.71 | 14.41% | -17.88% | -24.60% | -18.92% | -12.23% | -9.42% | 0.47 | -12.18 | 1.98 | 1.79 | -1.70 | 14348.00% | 199.00% | -3650.00% | -10.38% | 0.05 | -9.79% | 0.00% | 0.00% | 15.22% | -8.04 | -10.05 | 1.44 | 0.58 |
| GRDN | Guardian Pharmacy Service… | $28.99 | 1.84B | +3% | +293% | — | — | -16.12 | 8.03 | 0.93 | -27.12 | — | 19.59 | 19.89% | -5.12% | -7.11% | -83.14% | -46.27% | -24.00% | 0.26 | -19.19 | 1.05 | 0.71 | -0.75 | -55385.00% | 1742.00% | -2608.00% | 3.63% | 0.40 | 30.59% | 3.12% | -50.30% | 11.06% | -18.72 | 28.32 | 0.96 | 7.31 |
| MD | Pediatrix Medical Group, … | $21.69 | 1.86B | +77% | -41% | -77% | -70% | — | 1.93 | 0.87 | 6.67 | — | -4.05 | 24.66% | 12.07% | 8.64% | 0.00% | 16.78% | 0.00% | 0.76 | 6.43 | 1.66 | 1.62 | 1.04 | -26303.00% | -492.00% | 3689.00% | 15.14% | 0.59 | 24.00% | 0.00% | — | 14.02% | 7.92 | 7.24 | 0.96 | 2.03 |
| OGN | Organon & Co. | $6.38 | 1.66B | +645% | -40% | — | -41% | 9.98 | 2.48 | 0.30 | 7.87 | — | -0.41 | 54.09% | 20.67% | 3.01% | 30.56% | 6.35% | 1.44% | 11.70 | 2.55 | 1.82 | 0.84 | 6.41 | -7838.00% | -292.00% | -850.00% | 28.84% | 0.29 | 6.04% | 4.72% | 47.10% | 11.95% | 7.85 | 18.76 | 1.62 | 1.09 |
| PAHC | Phibro Animal Health Corp… | $41.15 | 1.67B | +57% | +183% | -89% | -1% | 32.91 | 5.56 | 1.23 | 15.48 | 1.75 | 8.38 | 30.85% | 8.52% | 3.72% | 17.80% | 9.58% | 4.12% | 2.67 | 3.32 | 2.76 | 1.04 | 4.72 | 188333.00% | 2737.00% | -976.00% | 2.63% | 0.27 | 5.11% | 1.22% | 40.30% | 1.22% | 20.57 | 54.33 | 1.75 | 2.84 |
| QDEL | QuidelOrtho Corporation | $27.37 | 1.86B | -22% | -67% | — | — | -1.35 | 0.80 | 0.56 | -8.47 | — | -2.38 | 46.67% | -33.67% | -41.45% | -46.15% | -18.22% | -18.56% | 1.46 | -5.18 | 1.50 | 0.64 | -5.40 | -4535.00% | -189.00% | -2596.00% | -5.42% | 0.11 | -1.65% | 0.00% | 0.00% | 0.00% | -4.50 | -49.82 | 1.51 | 0.29 |
| TLRY | Tilray Brands, Inc. | $1.28 | 1.43B | +103% | +103% | — | — | -0.19 | 0.28 | 0.51 | -0.23 | -0.03 | 0.57 | 29.29% | -277.93% | -266.25% | -88.71% | -84.34% | -68.11% | 0.22 | -55.23 | 2.46 | 1.35 | -0.05 | 65170.00% | 484.00% | 11348.00% | -30.24% | -0.34 | -4.97% | 0.00% | 0.00% | 12.04% | -0.22 | -3.87 | 0.60 | -5.74 |
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
- CEO
- Gregory J. Divis Jr.
- Employees
- 188
- Beta
- 1.48
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($48.66 ÷ —) − 1 = — (DCF, example).